Icon plc Aktie
Icon plc Aktie
Was spricht für und gegen Icon plc in den nächsten Jahren?
Pro
Kontra
Rendite von Icon plc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Icon plc | -0,44 % | 1,09 % | 5,04 % | 56,17 % | 14,39 % | - | - |
Alkermes plc | -1,79 % | 0,90 % | 0,00 % | -21,13 % | -10,40 % | 23,76 % | -0,88 % |
Ironwood Pharmaceuticals | 1,68 % | -20,67 % | -19,05 % | -35,68 % | -41,67 % | -37,70 % | - |
Sage Therapeutics Inc. | 1,35 % | -6,68 % | -25,36 % | -78,13 % | -46,20 % | -82,41 % | - |
Kommentare
News
ICON releases its ICON Cares 2023 Report
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is delivering on its
ICON Announces Pricing of USD 2 Billion Notes
ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting
ICON Reports First Quarter 2024 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024.
CEO, Dr